Onasemnogene abeparvovec (OA), an adeno-associated viral vector-based gene therapy, developed to carry a functional copy of the gene encoding full-length SMN protein directly to motor neuron, was the first gene therapy approved as treatment for SMA in the United States (7). Here, SMN1 is linked to proximal spinal muscular atrophy.